top of page
  • Writer's pictureNanoEntek

2023 Prostate Cancer: Estimation

Every year, the American Cancer Society make a statistical expectation on the number of new cancers and death rate in the Uniteds States of America. Rebecca L. et. al. estimated that the number of new cancers would be 1,958,310 and deaths caused from cancer would be 609,820 in the United States, 2023. This mathmatical derivation was made by observing the annual cancer incidence rate of 3% (2014 through 2019).

The mortality rate in cancer was assumed to be declining in 2% every year based on the statistical result from 2016 through 2020.

* The number of cancer death estimiation was derived by the data-driven joinpoint algorithm at the national levels as reported by the NCHS (2006 - 2020).

Here is the numbers from the report:

Estimated new cancer cases and deaths by sex in United States (2023)

Prostate (Cancer): 288,300

Prostate (Death): 34,700

Estimated new cases of prostate cancer by state

California : 26,970

Florida: 24,000

Illinois: 10,580

New York: 20,390

NorthCarolina: 10,040

Ohio: 10,980

Pennsylvania: 13,210

Tennessee: 6,280

Texas: 17,230

Probability (%) of developing invasive cancer

Male (Birth - 49 yrs): 0.2 (1 in 457)

Male (50 - 59 yrs): 1.8 (1 in 55)

Male (60 - 69 yrs): 5.2 (1 in 19)

Male (> 70 yrs): 9.2 (1 in 11)

Male (Birth to death): 12.6 (1 in 8)

Estimated New Cases


1st Prostate 288,300 (29%)

2nd Lung & bronchus 117,550 (12%)

3rd Colon & rectum 81,860 (8%)

Estimated Deaths


1st Lung & bronchus 67,160 (21%)

2nd Prostate 34,700 (11%)

3rd Colon & rectum 2,470 (9%)

Although the estimated incidence ratio of prostate related cancer is high in the evidence, the currnet survial rate is also high in prostate cancer(97%).

The graph design has been modified by Sehwan Oh (Technical support team of NanoEntek)

According to the data base earned from 2015 to 2019, over 70% had the localized prostate cancer regardless of ethnicity. Five-year relative survival rate for the prostate cancer in the United State from 2012 to 2018 showed that each stage had over >99%, >99%, >30%, 97% survival rate in Localized, Regional, Distant, Unstaged.

It was expected that the death rate might increase gradually in the past, but the slowing decline was observed from 1994 to 2013 (Around 3 to 4%) and from 2013 to 2020 (0.6%) on the prostate cancer mortality (in total, 53%). This phenomenon reflects the importance of earlty diagnosis of PSA testing and advanced treatment technologies and medications.

In summary, The data presented highlights the crucial importance of early detection of prostate cancer through regular PSA testing. With over 70% of cases being localized and a high five-year relative survival rate of >99%, it is clear that catching prostate cancer early greatly increases the chances of successful treatment and survival. The slowing decline in mortality rate over recent years further emphasizes the need for increased awareness and regular screening to ensure that prostate cancer is caught and treated as early as possible. With advanced treatment technologies and medications available, early detection through PSA testing is a key factor in improving outcomes for those affected by prostate cancer.


  1. Rebecca L. Siegel MPH et al, Cancer J Clin, Cancer statistics 2023, 2022

  2. PSA Package Insert, NanoEntek, Accessd 2023

[FREND System]

Rapid quantitative immunoassay analyzer

FREND is a quantitative immunoassay analyzing instrument that utilizes disposable cartridge to provide in vitro diagnostics results.

[Related Items]

FREND is a quantitative immunoassay analyzing instrument that utilizes disposable cartridge to provide in vitro diagnostics results.

Recent Posts

See All


bottom of page